- Data from Three Phase 2 Trials of Lead Aganocide Compound Anticipated in 2013 -
- Phase 3 Registration Trials Expected in 2014 -
EMERYVILLE, Calif., Feb. 20, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) "auriclosene" (pronounced awr-rih-CLO-zeen) for the Company's lead Aganocide® compound NVC-422. INNs facilitate the identification of active pharmaceutical ingredients, and each INN is a globally recognized unique name.Aganocides are NovaBay's first-in-class topical antimicrobial compounds, which are active against viruses, fungi, and bacteria, including the bacteria that grow and thrive under biofilm. Testing in-vitro and in-vivo has shown that these non-systemic, non-antibiotic compounds do not give rise to bacterial or fungal resistance. Phase 2 studies for auriclosene are currently ongoing in urology, ophthalmology, and dermatology. Dr. Ron Najafi, Chairman and Chief Executive Officer, said, "Obtaining the INN for our lead clinical compound NVC-422 confirms that our clinical development is on track, and we anticipate progression into Phase 3 development in each of our three Aganocide programs. We also intend to conduct a Phase 2a proof-of-concept study for auriclosene in an additional ophthalmic indication. NVC-422, now auriclosene, is the first of our proprietary Aganocides to receive a nonproprietary name." About NovaBay Pharmaceuticals, Inc. Going Beyond Antibiotics NovaBay Pharmaceuticals is a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of compounds, Aganocides® and NeutroPhase® Skin and Wound Cleanser. The Company's four core business units, DermaBay, UroBay, EyeBay and MediBay, are developing treatments that tackle infections in the dermatology, urology, ophthalmology, and wound care areas.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts